人疟原虫预防药（氯胍）的药代动力学及活化：药物代谢变异性的影响
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.
作者信息
Helsby N A, Ward S A, Edwards G, Howells R E, Breckenridge A M
机构信息
Department of Parasitology, Liverpool School of Tropical Medicine.
出版信息
Br J Clin Pharmacol. 1990 Oct;30(4):593-8. doi: 10.1111/j.1365-2125.1990.tb03818.x.
Abstract
- Based on the ratio of drug to active metabolite excreted in urine approximately 3% of a healthy Caucasian population showed a reduced ability to convert proguanil to cycloguanil. 2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1). 3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1). 4. The observed variability may result from the polymorphic metabolism of proguanil in man.
摘要
- 根据尿中排泄的药物与活性代谢物的比例，约3%的健康白种人群将氯胍转化为环氯胍的能力降低。2. 药代动力学分析表明，这一观察结果是由于这些个体中氯胍的口服清除率降低（分别为245、534和552毫升/分钟），与其他人群（858±482毫升/分钟）相比。3. 这些受试者中活性代谢物的血浆峰值浓度显著低于其他人群（分别为54.2、26.8和51.7纳克/毫升），其他人群为（141±45.2纳克/毫升）。4. 观察到的变异性可能是由于人体中氯胍的多态性代谢所致。
相似文献
1
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.人疟原虫预防药（氯胍）的药代动力学及活化：药物代谢变异性的影响
Br J Clin Pharmacol. 1990 Oct;30(4):593-8. doi: 10.1111/j.1365-2125.1990.tb03818.x.
2
Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults.健康肯尼亚成年人中氯胍代谢为活性代谢物环氯胍的变异性。
Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):492-5. doi: 10.1016/0035-9203(90)90010-c.
3
The multiple dose pharmacokinetics of proguanil.氯胍的多剂量药代动力学。
Br J Clin Pharmacol. 1993 Jun;35(6):653-6. doi: 10.1111/j.1365-2125.1993.tb04197.x.
4
Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.人體中氯胍及其活性代謝物環氯胍的穩態動力學
Chemotherapy. 1988;34(5):385-92. doi: 10.1159/000238597.
5
Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.怀孕和使用口服避孕药会降低氯胍向环氯胍的生物转化。
Eur J Clin Pharmacol. 2003 Oct;59(7):553-7. doi: 10.1007/s00228-003-0651-x. Epub 2003 Aug 30.
6
Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography.高效液相色谱法测定血浆、全血和尿液中的氯胍及其代谢物环氯胍和4-氯苯基双胍。
J Chromatogr. 1987 May 15;416(2):394-9. doi: 10.1016/0378-4347(87)80526-1.
7
Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.健康受试者中氯胍及其代谢产物的单剂量药代动力学
Br J Clin Pharmacol. 1987 Dec;24(6):775-80. doi: 10.1111/j.1365-2125.1987.tb03245.x.
8
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.人体中丙咪嗪代谢为活性代谢物环氯胍的个体间变异性。
Br J Clin Pharmacol. 1989 Jun;27(6):781-7. doi: 10.1111/j.1365-2125.1989.tb03440.x.
9
Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride.在每12小时服用100毫克盐酸氯胍后，氯胍和环氯胍的多剂量药代动力学研究。
Trop Med Parasitol. 1990 Sep;41(3):268-72.
10
Human pharmacokinetics of proguanil and its metabolites.氯胍及其代谢产物的人体药代动力学。
Trop Med Parasitol. 1987 Jun;38(2):77-80.
引用本文的文献
1
Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade.孕期抗癫痫药物的管理：过去十年的进展
Pharmaceutics. 2022 Dec 6;14(12):2733. doi: 10.3390/pharmaceutics14122733.
2
The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review.妊娠对青蒿素联合疗法（ACT）药代动力学特性的影响：一项系统评价。
Malar J. 2016 Feb 18;15:99. doi: 10.1186/s12936-016-1160-6.
3
Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.服用阿托伐醌-氯胍后，阿托伐醌在人体血浆中的抗疟活性持续时间较长。
Antimicrob Agents Chemother. 2005 Oct;49(10):4421-2. doi: 10.1128/AAC.49.10.4421-4422.2005.
4
Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.妊娠引起的药代动力学变化：基于机制的方法。
Clin Pharmacokinet. 2005;44(10):989-1008. doi: 10.2165/00003088-200544100-00001.
5
The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.阿托伐醌和氯胍用于治疗孕晚期孕妇单纯性恶性疟的药代动力学和药效学
Eur J Clin Pharmacol. 2005 Sep;61(8):573-82. doi: 10.1007/s00228-005-0969-7. Epub 2005 Jul 23.
6
Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.怀孕和使用口服避孕药会降低氯胍向环氯胍的生物转化。
Eur J Clin Pharmacol. 2003 Oct;59(7):553-7. doi: 10.1007/s00228-003-0651-x. Epub 2003 Aug 30.
7
Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.阿托伐醌/氯胍：用于预防恶性疟原虫疟疾的应用综述
Drugs. 2003;63(6):597-623. doi: 10.2165/00003495-200363060-00006.
8
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.细胞色素P450 2C19基因多态性的临床意义
Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002.
9
Recent Advances in the Prophylaxis and Treatment of Malaria.疟疾预防与治疗的最新进展
Curr Infect Dis Rep. 2001 Feb;3(1):68-76. doi: 10.1007/s11908-001-0061-0.
10
A mechanism for the synergistic antimalarial action of atovaquone and proguanil.阿托伐醌与氯胍协同抗疟作用的机制。
Antimicrob Agents Chemother. 1999 Jun;43(6):1334-9. doi: 10.1128/AAC.43.6.1334.
本文引用的文献
1
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.高加索人中美芬妥英羟化缺乏症：一种新的氧化药物代谢多态性的频率
Clin Pharmacol Ther. 1984 Dec;36(6):773-80. doi: 10.1038/clpt.1984.256.
2
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.美芬妥英的药物遗传学：人类一种新的药物羟基化多态性
Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938.
3
Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography.高效液相色谱法测定血浆、全血和尿液中的氯胍及其代谢物环氯胍和4-氯苯基双胍。
J Chromatogr. 1987 May 15;416(2):394-9. doi: 10.1016/0378-4347(87)80526-1.
4
Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.健康受试者中氯胍及其代谢产物的单剂量药代动力学
Br J Clin Pharmacol. 1987 Dec;24(6):775-80. doi: 10.1111/j.1365-2125.1987.tb03245.x.
5
A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.抗疟药物氯胍和氯丙胍的初步药代动力学研究。
J Pharm Pharmacol. 1987 Apr;39(4):261-5. doi: 10.1111/j.2042-7158.1987.tb06263.x.
6
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
J Pharmacol Exp Ther. 1987 Jan;240(1):216-22.
7
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.人体中丙咪嗪代谢为活性代谢物环氯胍的个体间变异性。
Br J Clin Pharmacol. 1989 Jun;27(6):781-7. doi: 10.1111/j.1365-2125.1989.tb03440.x.
8
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.人司巴丁N-氧化缺陷：一种新的药物遗传学缺陷。
Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059.
9
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件